POPULARITY
Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma.
Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer.
Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial, considerations for community oncologists when deciding whether to prescribe enfortumab vedotin plus pembrolizumab to patients with urothelial carcinoma, their advice for monitoring and managing treatment-related toxicities with this combination, and more.
Dr. Guru Sonpavde, Medical Director of Genitourinary Oncology (GU), AdventHealth Cancer Institute joins the podcast to dive deep into some of the clinical research that AdventHealth is pioneering and the work around a new bladder cancer therapy vaccine that represents the forefront of precision oncology.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This episode features Dr. Guru Sonpavde, GU Oncology, Phase I Director, Christopher K. Glanz Chair Bladder Cancer Research, Prof. UCF - AdventHealth Central Florida. Here, he discusses his recent NEJM paper on a Phase 3 trial tied to GU cancer and the drug combo of chemotherapy and immunotherapy improving survival rates from 11% to 22%, most focused on and excited about in the next 3-5 years, advice for evolving researchers, and more.Link to paper here: https://www.nejm.org/doi/full/10.1056/NEJMoa2309863
This chat offers a lesson on some of the latest pressing issues and trends in clinical research, bladder cancer, healthcare quality, electronic health records, and pharmaceutical industry relationships with academia from Dr. Guru Sonpavde, a cutting-edge, innovative medical oncologist and Bladder Cancer Director at the Dana Farber Cancer Institute, Associate Professor of Medicine at Harvard Medical School, member of Southwest Oncology Group (SWOG) and Bladder Cancer Task Force of the U.S. NCI Genitourinary Steering Committee. Highlights/Timeline: 4:45 – Perspectives on the physician patient relationship and how it has changed over the years 5:20 – Shared Decision-Making with patients 6:30 – Are patients more demanding than ever today and as a result present a challenge to physicians? 7:47 – Role of Innovative Clinical Research on the continuity of care? 10:08 – Memorable stories of novel treatments transforming patients' lives 10:42 – One of Dr. Sonpavde's patients was thought to be terminal having undergone 3 courses of chemotherapy for a cancer that has metastasized. This patient participated in a Phase I trial that combined a novel immunotherapy with an existing immunotherapy treatment and was given a very low likelihood of response yet the patient is still alive today in complete remission 2-years post treatment. 12:20 – Is our healthcare system designed to give physicians enough time to review patients' conditions to select the best course of therapy? It takes physicians a lot longer to enter data into EMR and requires more documentation than ever before 14:38 There is a huge unmet need in novel AI technology that is able to transcribe physician orders, comments accurately and patient level medical in order to close down the barrier between the patient and healthcare provider. 15:40 – Latest emerging treatments Dr. Sonpavde is most excited about in Bladder Cancer 16:23 – 1. Immunotherapy with Immune check-point inhibitors are a promising class of drugs that unleash immune T cells to fight the cancer in patients whose cancer progresses after the conventional platinum-based chemotherapy or even as first-line for metastatic cancer in patients who express PD-L1 protein or are ineligible for platinum-based chemotherapy. 2. Antibody-Drug Conjugates that are essentially a smart way of delivery of strong chemotherapy with more specific targeting of the tumor. 3. Erdafitinib, an FGFR3 inhibitor that works in patients who express this FGFR3 mutation that works in only 20 percent of patients. 4. Combining immunotherapy with Antibody Drug Conjugates is a very promising new approach 18:55 – Are there any particular new areas of research that are not addressed in bladder cancer? 19:31 – We still do not fully understand the biology of bladder cancer and have to improve our efforts in delivering the right treatment to the right patient - precision medicine. 1) We do not know who will benefit most from cisplatin chemotherapy 2) or who will benefit most from immunotherapy, and 3) we do not know the group of patients that will NOT benefit AT ALL from immunotherapy or chemotherapy because those are the populations that need the treatments the most. Thus we need biomarkers to predict tumor progression not just response to medication. 21:52 – What is Dr. Sonpavde's opinion about invasive versus non-invasive screening/testing in Bladder Cancer? 24:32 – Are Bladder Cancer patients expecting simpler methods of screening and longer survival? 28:47 – How can the Medical Affairs and R & D division of the pharmaceutical and medical device industries improve the quality of research to anchor it to patient outcomes in the future? 31:00 – What is one detail about clinical research would you teach patients to better manage their expectations? 33:15 – Are we improving in the transparency and speed of generating and communicating clinical trial results in healthcare? 37:16 – What is one specific medication on which you are working on at the moment? --- Support this podcast: https://anchor.fm/alloutcoach/support
Episode 15 of the Bladder Cancer Matters podcast is about a challenge facing many bladder cancer survivors: knowing that chemotherapy is the recommended treatment but finding out that it is not an option available to them. Its special guest is Dr. Guru Sonpavde, the Bladder Cancer Director at the Dana-Farber Cancer Institute in Boston. In this podcast, Rick and Dr. Sonpavde discuss: What are the different types of chemotherapy for bladder cancer? Why are some more effective than others? therapy is the standard treatment for many muscle-invasive and metastatic bladder cancer patients, but for some patients, this is not even an option. In bladder cancer, who gets platinum chemo? Suppose I can't have chemo. Can I have surgery? Would some of the things that make me ineligible for chemo make me ineligible for surgery? f I am ineligible, what are my alternatives today? What are their rates of success? Never miss an episode of the podcast by visiting your favorite podcasting platform, searching for Bladder Cancer Matters and clicking the "subscribe" button. You can also hear past episodes here.
Dr. Sonpavde discusses key data presented during the 2021 Genitourinary Cancers Symposium in urothelial carcinoma and anticipated research directions with immunotherapy, chemotherapy, and antibody-drug conjugates.
In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Guru Sonpavde about the current landscape of penile cancer. An extremely rare disease, penile cancer, according to estimates from the American Cancer Society, will affect approximately 2,200 men in 2020 in the United States. Sonpavde, director of the Bladder Cancer Program at Dana-Farber Cancer Institute in Boston, provides insight into this rare cancer and discusses why it’s difficult to treat patients with metastatic disease, as well as why research in this field is severely lacking. “It’s tough, logistically, to open a trial globally for a rare cancer, because what it means is you really have to open it in a lot of sites, a lot of institutions, to capture all these patients,” said Sonpavde in an interview with CURE®. “So, that obviously raises the issue of costs. Can you really open a trial in a thousand institutions that will only enroll a small number of patients?”
Dr. Guru Sonpavde, diretor do Dana-Farber Cancer Institute, USA, comenta três pôsteres apresentados na ASCO 2019, nos quais participa como autor.
Dr. Guru Sonpavde, diretor do Dana-Farber Cancer Institute, USA, destaca apresentação realizada na ASCO GU 2019 sobre modelo prognóstico para a sobrevida global de pacientes com carcinoma urotelial metastático
Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.
Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.
Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.
NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.
NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.
NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.
Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.
Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.
Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.